Clinical Precision | Radiomics & Multi-Modal AI

Optellum is trusted by industry & academic leaders

Why partner with Optellum?

Enterprise-grade-security-deployment-1024x648

Commercial growth

BioPharma | MedTech | Digital health

Patient discovery: Identify patients earlier and automatically, developing a funnel for finding more of the right patients.
Patient risk stratification: Optimize care decisions to guide procedures and increase opportunity for neoadjuvant and adjuvant treatments.^1,2
Patient acceleration: Accelerate diagnostic care pathway with discovery and prioritization of patients to shorten time to guideline-recommended treatment.^1,3

cf12b0ff-6466-4708-9267-454cc0bc4123-1-1-2-1

Clinical development

BioPharma

Patient enrollment: Identify the right patients and accelerate enrollment into clinical studies.^1,4,5
Predictive biomarkers RUO: Stratify patients earlier and more accurately to support precision care strategies.^6-9
Prognostic biomarkers RUO: Assess & monitor therapy response with robust biomarkers and automated volumetric quantification.^6-10

Automated-Data-Report-Retrieval-bg_3-1024x620

Research collaboration

Academic

Biomarker & algorithm development: Co-develop cutting-edge image-based biomarkers for diagnosis and therapy guidance.
Study recruitment: Accelerated patient recruitment with image-based endpoints to reduce study participant numbers.
Clinical validation: Validate innovative care pathways and tools with cutting-edge image-based AI and radiomics.

Data sharing

Academic | BioPharma | Digital health | MedTech | Provider

Imaging & installation exchange: Use our clinical solutions at your provider sites in exchange for data.
Data licensing: Access our high-value imaging datasets with flexible licensing options.
Data enrichment: Enrich and integrate our data with yours for research and clinical applications.

Early detection

Virtual Nodule Clinic Mass+

For Oncology partners

VNC with Tumor Dashboard discovers both lung nodules & masses, which may help clinicians to accelerate referral and prioritize candidates for neoadjuvant treatment.